Grants and Giving
Supports educational initiatives that advance clinical decision-making and improve healthcare professional knowledge in the management of transthyretin-mediated amyloidosis (ATTR-CM).
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (full proposal, RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple proposals may be funded; duration and total funds vary by project.
Summary: Supports independent educational initiatives advancing clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM).
Key Information: Only organizations (not individuals) may apply; ACCME accreditation required for medical education providers.
Description
Alnylam Pharmaceuticals’ Grants and Giving Office is soliciting proposals for independent educational activities that address gaps in the screening, diagnosis, monitoring, and management of transthyretin-mediated amyloidosis (ATTR-CM). This RFP (ALNY-RFP-TTR-13) seeks to fund initiatives that equip clinicians with actionable, evidence-based tools and frameworks for real-world clinical decision-making, with a focus on practical application across the patient journey. Eligible activities include CME-accredited programs, symposia, digital platforms, and live or virtual educational events. The intent is to improve patient outcomes by enhancing healthcare professionals' knowledge and implementation of best practices in ATTR-CM.
